Entries by Thomas Gabrielczyk

Novartis secures US$30m+ licence option from BioArctic

Following the commercial launch of BioArctic AB’s Alzheimer’s antibody lecanemab, the Swedish company has announced a new deal: it will receive an upfront payment of US$30m, granting the Swiss company access to BioArctic’s BrainTransporter platform to transport therapeutics for neurodegeneration across the blood-brain barrier

Merck and mantro enter the foodtech market

The laboratory division of Merck KGaA has, in partnership with the German company builder Mantro GmbH, established EdiMembre Inc, a Massachusetts-based company set to deploy Merck’s technologies for the production of structured meat alternatives – primarily Merck’s edible membranes.

Trump delays 250% tariffs on non-U.S. pharmaceuticals

U.S. President Donald Trump’s announcement regarding new tariffs on pharmaceutical goods imported into the United States has been delayed. Despite the President’s threat early last week that a tariff disclosure would come “within the next week or so,” the much-anticipated announcement is now expected to be “weeks away,” according to a report from Reuters citing industry and government sources.